The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | A machine learning model to analyze histopathological tissue in DLBCL
Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the utilization of deep learning algorithms to analyze whole-slide images in diffuse large B-cell lymphoma (DLBCL) pathology. This study used a self-trained computer vision pipeline learning system to classify subtypes of DLBCL and predict outcomes by identifying specific features in histopathological tissue. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Salarius, Acrotech, CRISPR, Seagen, Yingli; Research Funding: Pfizer, Ono, Astra Zeneca, Legend, Acrotech, Innate, CRISPR, Seagen, Merck, Drenbio, Yingli; Speakers Bureau: CuraBio, American Society of Hematology, American Society of Transplant and Cellular Therapy.
